Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes

American Heart Journal

Volumn 156, Issue 2, 2008, Pages 209-215

  Melloni, Chiara ^a   Alexander, Karen P ^a   Chen, Anita Y ^a   Newby, L Kristin ^a   Roe, Matthew T ^a   Allen LaPointe, Nancy M ^a   Pollack Jr , Charles V ^b   Gibler, W Brian ^c   Ohman, E Magnus ^a   Peterson, Eric D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING; BOLUS INJECTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG INFUSION; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; ST SEGMENT ELEVATION;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANTS; BODY WEIGHT; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; OBSERVATION; RISK;

EID: 47649094512     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.03.023     Document Type: Article

References (27)

1. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 336 (1990) 827-830
2. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 338 (1998) 1488-1497
3. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 339 (1998) 436-443
4. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40 (2002) 1366-1374
5. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 188S-203S
6. Raschke R.A., Reilly B.M., Guidry J.R., et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 119 (1993) 874-881
7. Hassan W.M., Flaker G.C., Feutz C., et al. Improved anticoagulation with a weight-adjusted heparin nomogram in patients with acute coronary syndromes: a randomized trial. J Thromb Thrombolysis 2 (1995) 245-249
8. Becker R.C., Ball S.P., Eisenberg P., et al. A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Am Heart J 137 (1999) 59-71
9. Hochman J.S., Wali A.U., Gavrila D., et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J 138 (1999) 313-318
10. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 330 (1994) 956-961
11. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 336 (1997) 1689-1697
12. Tolleson T.R., O'Shea J.C., Bittl J.A., et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol 41 (2003) 386-393
13. Granger C.B., Hirsh J., Califf R.M., et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 93 (1996) 870-878
14. Gilchrist I.C., Berkowitz S.D., Thompson T.D., et al. Heparin dosing and outcome in acute coronary syndromes: The GUSTO-IIb experience. Am Heart J 144 (2002) 73-80
15. Gore J.M., Spencer F.A., Goldberg R.J., et al. Use of heparins in non-ST-elevation acute coronary syndromes. Am J Med 120 (2007) 63-71
16. Blazing M.A., de Lemos J.A., White H.D., et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 292 (2004) 55-64
17. Hoekstra J.W., Pollack Jr. C.V., Roe M.T., et al. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. Acad Emerg Med 9 (2002) 1146-1155
18. LaPointe N.M.A., Chen A.Y., Alexander K.P., et al. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. Arch Intern Med 167 (2007) 1539-1544
19. Liang K. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13
20. Moscucci M., Fox K.A.A., Cannon C.P., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1815-1823
21. Morabia A. Heparin doses and major bleedings. The Lancet 1 (1986) 1278-1279
22. Lee M.S., Wali A.U., Menon V., et al. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. J Thromb Thrombolysis 14 (2002) 91-101
23. Harrington R.A., Becker R.C., Ezekowitz M., et al. Antithrombotic therapy for coronary artery disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 513S-548S
24. Cabana M.D., Rand C.S., Powe N.R., et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282 (1999) 1458-1465
25. Freedman J.E., Becker R.C., Adams J.E., et al. Medication errors in acute cardiac care: an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke. Circulation 106 (2002) 2623-2629
26. Teich J.M., Merchia P.R., Schmiz J.L., et al. Effects of computerized physician order entry on prescribing practices. Arch Intern Med 160 (2000) 2741-2747
27. Alexander K.P., Chen A.Y., Roe M.T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116